Zheng Quan Zhi Xing·2025-07-07 04:12Core Viewpoint - Haisco Pharmaceutical Group Co., Ltd. is applying for a specific issuance of A-shares, which is expected to enhance its capital strength and support the development of innovative drugs, thereby improving its market position and long-term sustainability [1][24]. Group 1: Issuance Details - The lead underwriter for the issuance is CITIC Securities Co., Ltd. [2] - The project representatives from CITIC Securities include Shen Ziquan and Wang Qi, with a team of other members involved in the underwriting process [2][3]. - The issuance aims to raise funds for new drug research and to supplement working capital, which is aligned with the company's strategic development goals [24]. Group 2: Company Information - Haisco Pharmaceutical Group Co., Ltd. has a registered capital of 1,119,917,970 RMB and is listed on the Shenzhen Stock Exchange under the stock code 002653 [4]. - The company specializes in the sale of chemical products, medical research, and development, among other activities [4]. - As of March 31, 2025, the major shareholders include Wang Junmin, who holds 35.68% of the shares, and his spouse, Shen Ping, who holds 4.43% [16][17]. Group 3: Financial Performance - The company reported an operating income of 89,201.30 million RMB for the year 2024, with a net profit attributable to shareholders of 4,661.19 million RMB [16]. - The comprehensive gross margin for 2024 was 70.29%, indicating a slight decrease from the previous year [16]. - The total assets of the company as of March 31, 2025, amounted to 692,474.32 million RMB, with total liabilities of 281,085.39 million RMB [16]. Group 4: Corporate Governance - The board of directors approved the issuance plan on February 27, 2025, and further discussions were held on April 3, 2025, confirming the company's readiness for the issuance [24]. - The company has undergone necessary due diligence and compliance checks as per regulatory requirements, ensuring that the issuance aligns with legal and industry standards [23][24].